
NICE has reached a decision in its final appraisal determination of Teva’s Cinqaero (reslizumab), recommending the drug’s use as an …

The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

